The Alliance for Regenerative Medicine Announces Agenda for Regenerative Medicine Insight Track at Biotech Showcase on January 10 and 11 in San Francisco
Speakers Include Advanced Cell Technology, Athersys, Cytori, Dendreon, Genzyme-Sanofi, Johnson & Johnson, Mesoblast, and Shire
(firmenpresse) - WASHINGTON, DC -- (Marketwire) -- 01/05/12 -- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine (RM) community, today released the agenda for its second annual State of the Industry Briefing and RM Insight Track. The meeting will take place on January 10 - 11, 2012 at the Park 55 Wyndham in San Francisco.
The Regenerative Medicine State of the Industry Briefing will focus on recent developments and the future outlook for regenerative medicine, cell therapy and other advanced therapeutics. A full day of panels focused on several disease areas will follow the briefing as part of the Regenerative Medicine Insight track at the Biotech Showcase 2012. The panels will be moderated by key analysts in the sector. Please see agenda below:
Gil Van Bokkelen, CEO, Athersys (Moderator)
Silviu Itescu, CEO, Mesoblast
Tim Mayleben, CEO of Aaastrom
Gary Rabin, CEO, Advanced Cell Technology
Robin Smith, CEO, NeoStem
Leanna Caron, VP & GM of Cell Therapy & Regenerative Medicine, Genzyme-Sanofi
Ed Field, COO, Aldagen
Jay Seigal, CBO, Johnson & Johnson
Dean Tozer, Senior VP of Corporate Development, ABH-Shire
Susan Solomon, CEO, New York Stem Cell Foundation
Analyst: Jason Butler, JMP Securities
Amorcyte, Andrew Pecora, CSO
Cytori, Marc Hendrick, President
Athersys, Gil Van Bokkelen, CEO
Mesoblast, Silviu Itescu, CEO
Analyst: Ren Benjamin, Rodman and Renshaw
Aastrom, Brian Gibson, VP Finance
ReNeuron, Michael Hunt, CEO
Aldagen, Ed Field, COO
Tissue Genesis, Anton Krucky, CEO
SanBio, Keita Mori, CEO
Analyst: Steve Brozak, WBB Securities
StemCells, Inc., Martin McGlynn, CEO
NeuralStem, Richard Garr, CEO
InVivo, Frank Reynolds, Chairman of the Board, CEO, CFO,
Advanced Cell Technology, Gary Rabin, CEO
Analyst: Kai Makay, Roth Capital
Tengion, Mark Stejbach, VP, CCO
Allocure, John Wirthlin, COO
Tigenix, Eduardo Bravo, CEO
Q Therapeutics, Deborah Eppstein, CEO
Analyst: Jeffery Cohen, Ladenburg Thalmann & Co.
ISTO, Scott Gill, CFO
Organovo, Keith Murphy, CEO
ABH - Shire, Dean Tozer, Senior VP of Corporate Development
Healthpoint, Rob Bancroft, VP, Strategic and Corporate Development
Axogen, Karen Zaderej, CEO
Harvard Biosciences, David Green, CEO
Analyst: Stephen Dunn, LifeTech Capital
Dendreon, David L. Urdal, Executive VP, CSO
Prima BioMed, Martin Rogers, CEO
ImmunoCellular, Manish Singh, CEO
Coronado, Bobby Sandage, CEO
bluebird bio, Jeffrey Walsh, COO
NexImmune, Ken Carter, CEO
Maxcyte, Doug Doerfler, CEO
To learn more and to register for the conference, please contact Rob Margolin at (646) 201-4192. Registration is complimentary for credentialed members of the media and the investment community. The State of the Industry briefing is open to the public, but attendance at the disease panels will require registration for individuals without press or investor credentials.
Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of the annual JP Morgan Healthcare Conference, one of the most important healthcare industry events of the year which attracts thousands of healthcare and life science business executives to San Francisco. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group. Please visit their website for more information: .
ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM in September 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit .
Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.01.2012 - 10:58 Uhr
Sprache: Deutsch
News-ID 1070362
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WASHINGTON, DC
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 112 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The Alliance for Regenerative Medicine Announces Agenda for Regenerative Medicine Insight Track at Biotech Showcase on January 10 and 11 in San Francisco
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Alliance for Regenerative Medicine (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
